Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trialResearch in context

Summary: Background: The SARS-CoV-2 virus continues to evolve with recent variants such as the omicron sub-variants potentially exhibiting increased transmissibility. Of note, the XBB.1.5 variant has been associated with vaccine-breakthrough cases. We utilised the same platform previously used to d...

Descripció completa

Dades bibliogràfiques

Autors principals:	Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Rammohan Reddy Mogulla, Vijay Yerroju, Chirag Dhar, Siddalingaiah Ningaiah, Mallikarjuna Panchakshari, Chandrashekhar S. Gillurkar, Manish Narang, Shivnitwar Sachin Kisan, A. Venkateshwar Rao
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-09-01
Col·lecció:	The Lancet Regional Health - Southeast Asia
Matèries:	Randomised controlled trial COVID-19 XBB.1.5 variant Subunit vaccine Booster
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2772368225001131
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!